{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T18:07:20Z","timestamp":1791050840316,"version":"4.1.0"},"reference-count":38,"publisher":"American Society of Hematology","issue":"12","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2004,12,1]]},"abstract":"<jats:p>We carried out HLA-matched related (n = 16) and unrelated (n = 17) hematopoietic cell transplantation (HCT) in 33 patients with relapsed and refractory mantle cell lymphoma after nonmyeloablative conditioning with fludarabine and 2 Gy total body irradiation. Postgrafting immunosuppression consisted of cyclosporine and mycophenolate mofetil. Fourteen patients had failed high-dose autologous HCT. Of the 33 patients studied, 31 had stable engraftment, whereas 2 patients experienced nonfatal graft rejections. The incidences of acute grades II, III, and IV, and chronic graft-versus-host disease (GVHD) were 27%, 17%, 13%, and 64%, respectively. The overall response rate in the 20 patients with measurable disease at the time of HCT was 85% (n = 17; 75% complete remissions [CR] and 10% partial remissions [PR]), whereas 3 patients had progressive disease. Only one of the 17 patients who responded and none of the 13 who received transplants in CR had disease relapse with a median follow-up of 24.6 months. Relapse and nonrelapse mortalities were 9% and 24%, respectively, at 2 years. The Kaplan-Meier probabilities of overall and disease-free survivals at 2 years were 65% and 60%, respectively. Allogeneic HCT after nonmyeloablative conditioning is a promising salvage strategy for patients with relapsed and refractory mantle cell lymphoma. The high response and low relapse rates with this approach suggest that mantle cell lymphoma is susceptible to graft-versus-tumor responses.<\/jats:p>","DOI":"10.1182\/blood-2004-06-2275","type":"journal-article","created":{"date-parts":[[2004,8,10]],"date-time":"2004-08-10T21:13:08Z","timestamp":1092172388000},"page":"3535-3542","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":220,"title":["Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma"],"prefix":"10.1182","volume":"104","author":[{"given":"Michael B.","family":"Maris","sequence":"first","affiliation":[{"name":"From the Fred Hutchinson Cancer Research Center, the University of Washington, and the Seattle Veterans Affairs Medical Center, Seattle, WA; Stanford University, Palo Alto, CA; Oregon Health and Science University, Portland, OR; Baylor University, Dallas, TX; Emory University, Atlanta, GA; and the University of Utah, Salt Lake City, UT."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda M.","family":"Sandmaier","sequence":"additional","affiliation":[{"name":"From the Fred Hutchinson Cancer Research Center, the University of Washington, and the Seattle Veterans Affairs Medical Center, Seattle, WA; Stanford University, Palo Alto, CA; Oregon Health and Science University, Portland, OR; Baylor University, Dallas, TX; Emory University, Atlanta, GA; and the University of Utah, Salt Lake City, UT."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry E.","family":"Storer","sequence":"additional","affiliation":[{"name":"From the Fred Hutchinson Cancer Research Center, the University of Washington, and the Seattle Veterans Affairs Medical Center, Seattle, WA; Stanford University, Palo Alto, CA; Oregon Health and Science University, Portland, OR; Baylor University, Dallas, TX; Emory University, Atlanta, GA; and the University of Utah, Salt Lake City, UT."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Chauncey","sequence":"additional","affiliation":[{"name":"From the Fred Hutchinson Cancer Research Center, the University of Washington, and the Seattle Veterans Affairs Medical Center, Seattle, WA; Stanford University, Palo Alto, CA; Oregon Health and Science University, Portland, OR; Baylor University, Dallas, TX; Emory University, Atlanta, GA; and the University of Utah, Salt Lake City, UT."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monic Jain","family":"Stuart","sequence":"additional","affiliation":[{"name":"From the Fred Hutchinson Cancer Research Center, the University of Washington, and the Seattle Veterans Affairs Medical Center, Seattle, WA; Stanford University, Palo Alto, CA; Oregon Health and Science University, Portland, OR; Baylor University, Dallas, TX; Emory University, Atlanta, GA; and the University of Utah, Salt Lake City, UT."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard T.","family":"Maziarz","sequence":"additional","affiliation":[{"name":"From the Fred Hutchinson Cancer Research Center, the University of Washington, and the Seattle Veterans Affairs Medical Center, Seattle, WA; Stanford University, Palo Alto, CA; Oregon Health and Science University, Portland, OR; Baylor University, Dallas, TX; Emory University, Atlanta, GA; and the University of Utah, Salt Lake City, UT."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Agura","sequence":"additional","affiliation":[{"name":"From the Fred Hutchinson Cancer Research Center, the University of Washington, and the Seattle Veterans Affairs Medical Center, Seattle, WA; Stanford University, Palo Alto, CA; Oregon Health and Science University, Portland, OR; Baylor University, Dallas, TX; Emory University, Atlanta, GA; and the University of Utah, Salt Lake City, UT."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelia A.","family":"Langston","sequence":"additional","affiliation":[{"name":"From the Fred Hutchinson Cancer Research Center, the University of Washington, and the Seattle Veterans Affairs Medical Center, Seattle, WA; Stanford University, Palo Alto, CA; Oregon Health and Science University, Portland, OR; Baylor University, Dallas, TX; Emory University, Atlanta, GA; and the University of Utah, Salt Lake City, UT."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Pulsipher","sequence":"additional","affiliation":[{"name":"From the Fred Hutchinson Cancer Research Center, the University of Washington, and the Seattle Veterans Affairs Medical Center, Seattle, WA; Stanford University, Palo Alto, CA; Oregon Health and Science University, Portland, OR; Baylor University, Dallas, TX; Emory University, Atlanta, GA; and the University of Utah, Salt Lake City, UT."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"Storb","sequence":"additional","affiliation":[{"name":"From the Fred Hutchinson Cancer Research Center, the University of Washington, and the Seattle Veterans Affairs Medical Center, Seattle, WA; Stanford University, Palo Alto, CA; Oregon Health and Science University, Portland, OR; Baylor University, Dallas, TX; Emory University, Atlanta, GA; and the University of Utah, Salt Lake City, UT."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G.","family":"Maloney","sequence":"additional","affiliation":[{"name":"From the Fred Hutchinson Cancer Research Center, the University of Washington, and the Seattle Veterans Affairs Medical Center, Seattle, WA; Stanford University, Palo Alto, CA; Oregon Health and Science University, Portland, OR; Baylor University, Dallas, TX; Emory University, Atlanta, GA; and the University of Utah, Salt Lake City, UT."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021218125954200_REF1","unstructured":"Grossbard MLG. Malignant Lymphomas. Hamilton, Ontario: BC Decker Inc; 2002. Steele Jr GDS, Phillips TL, Chabner BC, eds. Atlas of Clinical Oncology."},{"key":"2020021218125954200_REF2","doi-asserted-by":"crossref","unstructured":"Densmore JJ, Williams ME. Mantle cell lymphoma. Curr Treat Options Oncol.2003;4: 281-287.","DOI":"10.1007\/s11864-003-0003-1"},{"key":"2020021218125954200_REF3","doi-asserted-by":"crossref","unstructured":"Fisher RI, Dahlberg S, Nathwani BN, Banks PM, Miller TP, Grogan TM. A clinical analysis of two indolent lymphoma entities: mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories): a Southwest Oncology Group study. Blood.1995;85: 1075-1082.","DOI":"10.1182\/blood.V85.4.1075.bloodjournal8541075"},{"key":"2020021218125954200_","doi-asserted-by":"crossref","unstructured":"Bosch F, Lopez-Guillermo A, Campo E, et al. Mantle cell lymphoma: presenting features, response to therapy, and prognostic factors. Cancer.1998;82: 567-575.","DOI":"10.1002\/(SICI)1097-0142(19980201)82:3<567::AID-CNCR20>3.0.CO;2-Z"},{"key":"2020021218125954200_","doi-asserted-by":"crossref","unstructured":"Romaguera JE, Khouri IF, Kantarjian HM, et al. Untreated aggressive mantle cell lymphoma: results with intensive chemotherapy without stem cell transplant in elderly patients. Leukemia & Lymphoma.2000;39: 77-85.","DOI":"10.3109\/10428190009053541"},{"key":"2020021218125954200_REF6","doi-asserted-by":"crossref","unstructured":"Howard OM, Gribben JG, Neuberg DS, et al. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. J Clin Oncol.2002;20: 1288-1294.","DOI":"10.1200\/JCO.20.5.1288"},{"key":"2020021218125954200_REF7","doi-asserted-by":"crossref","unstructured":"Velders GA, Kluin-Nelemans JC, De Boer CJ, et al. Mantle-cell lymphoma: a population-based clinical study. J Clin Oncol.1996;14: 1269-1274.","DOI":"10.1200\/JCO.1996.14.4.1269"},{"key":"2020021218125954200_REF8","doi-asserted-by":"crossref","unstructured":"Khouri IF, Saliba RM, Okoroji GJ, Acholonu SA, Champlin RE. Long-term follow-up of autologous stem cell transplantation in patients with diffuse mantle cell lymphoma in first disease remission: the prognostic value of \u03b22-microglobulin and the tumor score. Cancer.2003;98: 2630-2635.","DOI":"10.1002\/cncr.11838"},{"key":"2020021218125954200_REF9","doi-asserted-by":"crossref","unstructured":"Milpied N, Gaillard F, Moreau P, et al. High-dose therapy with stem cell transplantation for mantle cell lymphoma: results and prognostic factors, a single center experience. Bone Marrow Transplant.1998;22: 645-650.","DOI":"10.1038\/sj.bmt.1701400"},{"key":"2020021218125954200_","doi-asserted-by":"crossref","unstructured":"Mangel J, Leitch HA, Connors JM, et al. Intensive chemotherapy and autologous stem-cell transplantation plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage mantle-cell lymphoma: a matched pair analysis. Ann Oncol.2004;15: 283-290.","DOI":"10.1093\/annonc\/mdh069"},{"key":"2020021218125954200_REF11","doi-asserted-by":"crossref","unstructured":"Gianni AM, Magni M, Martelli M, et al. Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen). Blood.2003;102: 749-755.","DOI":"10.1182\/blood-2002-08-2476"},{"key":"2020021218125954200_REF12","doi-asserted-by":"crossref","unstructured":"Vose JM, Bierman PJ, Weisenburger DD, et al. Autologous hematopoietic stem cell transplantation for mantle cell lymphoma. Biol Blood Marrow Transplant.2000;6: 640-645.","DOI":"10.1016\/S1083-8791(00)70030-9"},{"key":"2020021218125954200_REF13","doi-asserted-by":"crossref","unstructured":"Vandenberghe E, Ruiz dE, Loberiza FR, et al. Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries. Br J Haematol.2003;120: 793-800.","DOI":"10.1046\/j.1365-2141.2003.04140.x"},{"key":"2020021218125954200_REF14","doi-asserted-by":"crossref","unstructured":"Gopal AK, Rajendran JG, Petersdorf SH, et al. High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. Blood.2002;99: 3158-3162.","DOI":"10.1182\/blood.V99.9.3158"},{"key":"2020021218125954200_REF15","doi-asserted-by":"crossref","unstructured":"Faulkner RD, Craddock C, Byrne JL, et al. BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients. Blood.2004;103: 428-434.","DOI":"10.1182\/blood-2003-05-1406"},{"key":"2020021218125954200_REF16","doi-asserted-by":"crossref","unstructured":"Robinson SP, Goldstone AH, Mackinnon S, et al. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood.2002;100: 4310-4316.","DOI":"10.1182\/blood-2001-11-0107"},{"key":"2020021218125954200_REF17","doi-asserted-by":"crossref","unstructured":"Kroger N, Hoffknecht M, Kruger W, et al. Allogeneic bone marrow transplantation for refractory mantle cell lymphoma. Ann Hematol.2000;79: 578-580.","DOI":"10.1007\/s002770000196"},{"key":"2020021218125954200_REF18","doi-asserted-by":"crossref","unstructured":"Kro\u0308ger N, Hoffknecht M, Dreger P, et al. Long-term disease-free survival of patients with advanced mantle-cell lymphoma following high-dose chemotherapy. Bone Marrow Transplant.1998;21: 55-57.","DOI":"10.1038\/sj.bmt.1701033"},{"key":"2020021218125954200_REF19","doi-asserted-by":"crossref","unstructured":"Izutsu K, Kanda Y, Ohno H, et al. Unrelated bone marrow transplantation for non-Hodgkin lymphoma: a study from the Japan Marrow Donor Program. Blood.2004;103: 1955-1960.","DOI":"10.1182\/blood-2003-03-0937"},{"key":"2020021218125954200_","doi-asserted-by":"crossref","unstructured":"van Besien K, Loberiza FRJ, Bajorunaite R, et al. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood.2003;102: 3521-3529.","DOI":"10.1182\/blood-2003-04-1205"},{"key":"2020021218125954200_REF21","doi-asserted-by":"crossref","unstructured":"Peniket AJ, Ruiz DEM, Taghipour G, et al. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant.2003;31: 667-678.","DOI":"10.1038\/sj.bmt.1703891"},{"key":"2020021218125954200_REF22","unstructured":"van Besien K, Sobocinski KA, Rowlings PA, et al. Allogeneic bone marrow transplantation for low-grade lymphoma. Blood.1998;92: 1832-1836."},{"key":"2020021218125954200_REF23","doi-asserted-by":"crossref","unstructured":"Khouri IF, Lee MS, Saliba RM, et al. Nonablative allogeneic stem-cell transplantation for advanced\/recurrent mantle-cell lymphoma. J Clin Oncol.2003;21: 4407-4412.","DOI":"10.1200\/JCO.2003.05.501"},{"key":"2020021218125954200_REF24","doi-asserted-by":"crossref","unstructured":"McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versustumor effects. Blood.2001;97: 3390-3400.","DOI":"10.1182\/blood.V97.11.3390"},{"key":"2020021218125954200_REF25","doi-asserted-by":"crossref","unstructured":"Maris MB, Niederwieser D, Sandmaier BM, et al. HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. Blood.2003;102: 2021-2030.","DOI":"10.1182\/blood-2003-02-0482"},{"key":"2020021218125954200_REF26","doi-asserted-by":"crossref","unstructured":"Radich JP, Gooley T, Sanders JE, Anasetti C, Chauncey T, Appelbaum FR. Second allogeneic transplantation after failure of first autologous transplantation. Biol Blood Marrow Transplant.2000;6: 272-279.","DOI":"10.1016\/S1083-8791(00)70009-7"},{"key":"2020021218125954200_REF27","doi-asserted-by":"crossref","unstructured":"Petersdorf EW, Gooley TA, Anasetti C, et al. Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient. Blood.1998;92: 3515-3520.","DOI":"10.1182\/blood.V92.10.3515"},{"key":"2020021218125954200_REF28","doi-asserted-by":"crossref","unstructured":"Charlson ME, Sax FL, MacKenzie CR, Fields SD, Braham RL, Douglas RG Jr. Assessing illness severity: does clinical judgment work? J Chronic Dis.1986;39: 439-452.","DOI":"10.1016\/0021-9681(86)90111-6"},{"key":"2020021218125954200_","doi-asserted-by":"crossref","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis.1987;40: 373-383.","DOI":"10.1016\/0021-9681(87)90171-8"},{"key":"2020021218125954200_REF30","doi-asserted-by":"crossref","unstructured":"Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol.1994;47: 1245-1251.","DOI":"10.1016\/0895-4356(94)90129-5"},{"key":"2020021218125954200_REF31","unstructured":"Sullivan KM. Graft-versus-host-disease. In: Thomas ED, Blume KG, Forman SJ, eds. Hematopoietic Cell Transplantation, 2nd Edition. Boston: Blackwell Science; 1999: 515-536."},{"key":"2020021218125954200_REF32","doi-asserted-by":"crossref","unstructured":"Durnam DM, Anders KR, Fisher L, O'Quigley JO, Bryant EM, Thomas ED. Analysis of the origin of marrow cells in bone marrow transplant recipients using a Y-chromosome-specific in situ hybridization assay. Blood.1989;74: 2220-2226.","DOI":"10.1182\/blood.V74.6.2220.2220"},{"key":"2020021218125954200_REF33","doi-asserted-by":"crossref","unstructured":"Ugozzoli L, Yam P, Petz LD, et al. Amplification by the polymerase chain reaction of hypervariable regions of the human genome for evaluation of chimerism after bone marrow transplantation. Blood.1991;77: 1607-1615.","DOI":"10.1182\/blood.V77.7.1607.1607"},{"key":"2020021218125954200_REF34","doi-asserted-by":"crossref","unstructured":"Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood.1996;87: 4990-4997.","DOI":"10.1182\/blood.V87.12.4990.bloodjournal87124990"},{"key":"2020021218125954200_REF35","doi-asserted-by":"crossref","unstructured":"Hiddemann W, Unterhalt M, Herrmann R, et al. Mantle-cell lymphomas have more widespread disease and a slower response to chemotherapy compared with follicle-center lymphomas: results of a prospective comparative analysis of the German Low-Grade Lymphoma Study Group. J Clin Oncol.1998;16: 1922-1930.","DOI":"10.1200\/JCO.1998.16.5.1922"},{"key":"2020021218125954200_REF36","doi-asserted-by":"crossref","unstructured":"Khouri IF, Romaguera J, Kantarjian H, et al. Hyper-CVAD and high-dose methotrexate\/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol.1998;16: 3803-3809.","DOI":"10.1200\/JCO.1998.16.12.3803"},{"key":"2020021218125954200_REF37","doi-asserted-by":"crossref","unstructured":"Diaconescu R, Flowers CR, Storer B, et al. Morbidity and mortality with nonmyeloablative compared to myeloablative conditioning before hematopoietic cell transplantation from HLA matched related donors. Blood.2004;104: 1550-1558.","DOI":"10.1182\/blood-2004-03-0804"},{"key":"2020021218125954200_REF38","doi-asserted-by":"crossref","unstructured":"Sorror ML, Maris MB, Storer B, et al. Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplant comorbidities. Blood.2004;104: 961-968.","DOI":"10.1182\/blood-2004-02-0545"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/104\/12\/3535\/1703747\/zh802304003535.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/104\/12\/3535\/1703747\/zh802304003535.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,2]],"date-time":"2020-04-02T19:33:59Z","timestamp":1585856039000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/104\/12\/3535\/89046\/Allogeneic-hematopoietic-cell-transplantation"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,12,1]]},"references-count":38,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2004,12,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2004-06-2275","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,12,1]]}}}